Track record · closed signal

Hims & Hers Health, Inc. (HIMS) — closed signal from September 4, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on December 3, 2025.

Predicted vs. what happened

HIMS price · publication thesis → realized outcomesplit-adjusted
$46.56 Published $60.53 Target $37.07 Window close $65.30 Peak
$45.00 – $46.60Entry zone — fair-value band
$46.56Published — price the day we called it
$60.53Target — the price the thesis aimed for
$65.30Peak — highest point inside the window, not a realized return
$37.07Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 25 days.

Peak price
$65.30
peak on October 15, 2025 — not a realized return
Peak gain
+40.2%
peak, from the publication price
Window close
$37.07
end-of-window price, context only
Days to target
25
Window
September 4, 2025 – December 3, 2025

The thesis — published September 4, 2025

Predicted growth
+30%
over the measurement window
Target price
$60.53
the price the thesis aimed for
Entry zone
$45.00 – $46.60
the fair-value band we waited for
Price at publication
$46.56
published September 4, 2025
Confidence
72%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

A recent court win cleared a cloud over the stock and drew unusually strong trading interest, helping the uptrend. Investor mood is upbeat, and the recent average price is rising, but price swings are still large. The business is growing across more product areas, so the next few months could stay favorable if execution remains solid. Be ready for dips and manage position size.

Primary drivers

  • Court decision cleared a worry that had been holding shares back recently
  • Strong price trend lately and more options trading than usual seen
  • Adding more product areas, which can bring in more customers
  • Price swings are big right now, so buying in small steps can reduce risk

How it played out

HIMS: target reached in 25 days

Lyra published HIMS on 2025-09-04 at 46.56 with expected growth of 30%. The thesis pointed to a court decision that had cleared a recent worry, strong trading interest, an uptrend, broader product areas, and large price swings that called for smaller steps.

Inside the window, HIMS reached the 60.53 target in 25 days. It peaked at 65.3 on 2025-10-15, up 40.2%, then fell back and ended at 37.07 on 2025-12-03. The thesis played out on the target. The move did not hold through the close.

What happened during the window

On 2025-11-04, MarketWatch reported that Hims & Hers had said late Monday it was in active discussions with Novo Nordisk about making Wegovy available on its platform. The same report said the company reported third-quarter revenue of $599 million and subscriber growth of 21% to 2.5 million.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HIMS signals